Serveur d'exploration Tocilizumab - Checkpoint (Ncbi)

Index « Mesh.i » - entrée « Opportunistic Infections »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Ophthalmoscopy < Opportunistic Infections < Opsonin Proteins  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 28.
[0-20] [0 - 20][0 - 28][20-27][20-40]
Ident.Authors (with country if any)Title
000031 (2006) J. Ogawa ; M. Harigai ; T. Akashi ; K. Nagasaka ; F. Suzuki ; S. Tominaga ; N. MiyasakaExacerbation of chronic active Epstein-Barr virus infection in a patient with rheumatoid arthritis receiving humanised anti-interleukin-6 receptor monoclonal antibody.
000240 (2010) J L Nam [Royaume-Uni] ; K L Winthrop ; R F Van Vollenhoven ; K. Pavelka ; G. Valesini ; E M A. Hensor ; G. Worthy ; R. Landewé ; J S Smolen ; P. Emery ; M H BuchCurrent evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA.
000374 (2011) Khadija Baccouche [France] ; Jérémie Sellam ; Sarah Guegan ; Sélim Aractingi ; Francis BerenbaumCrusted Norwegian scabies, an opportunistic infection, with tocilizumab in rheumatoid arthritis.
000437 (2011) Takao Koike [Japon] ; Masayoshi Harigai ; Shigeko Inokuma ; Naoki Ishiguro ; Junnosuke Ryu ; Tsutomu Takeuchi ; Syuji Takei ; Yoshiya Tanaka ; Kyoko Ito ; Hisashi YamanakaPostmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients.
000463 (2012) Yusuf Yazici [États-Unis] ; Jeffrey R. Curtis ; Akgun Ince ; Herbert Baraf ; Raymond L. Malamet ; Lichen L. Teng ; Arthur KavanaughEfficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study.
000608 (2012) Jatinder P. Ahluwalia [États-Unis]Immunotherapy in inflammatory bowel disease.
000658 (2013) Daniel Wendling ; Sylvère Hugonnot ; Florent Montini ; Clément PratiInfluenza H1N1 infection in a patient with rheumatoid arthritis treated with tocilizumab.
000662 (2013) Morgane Milin [France] ; Marie Acquitter ; Rozenn Le Berre ; Bruno Sassolas ; Valérie Devauchelle-Pensec ; Divi CornecBartonella henselae infection during tocilizumab therapy.
000701 (2012) Eric M. Ruderman [États-Unis]Overview of safety of non-biologic and biologic DMARDs.
000961 (2014) Hiroki Wakabayashi [Japon] ; Shinya Takigawa [Japon] ; Masahiro Hasegawa [Japon] ; Takuya Kakimoto [Japon] ; Kakunoshin Yoshida [Japon] ; Akihiro Sudo [Japon]Polyarticular late infection of total joint arthroplasties in a patient with rheumatoid arthritis treated with anti-interleukin-6 therapy.
000998 (2014) Sofia Ramiro [Pays-Bas] ; Cécile Gaujoux-Viala ; Jackie L. Nam ; Josef S. Smolen ; Maya Buch ; Laure Gossec ; Désirée Van Der Heijde ; Kevin Winthrop ; Robert LandewéSafety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis.
000A83 (2016) Sulaiman M. Al-Mayouf [Arabie saoudite] ; Abdullatif Alenazi [Arabie saoudite] ; Hind Aljasser [Arabie saoudite]Biologic agents therapy for Saudi children with rheumatic diseases: indications and safety.
000B96 (2015) Huifeng Yun ; Fenglong Xie ; Elizabeth Delzell ; Lang Chen ; Emily B. Levitan ; James D. Lewis ; Kenneth G. Saag ; Timothy Beukelman ; Kevin Winthrop ; John W. Baddley ; Jeffrey R. CurtisRisks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy.
000C76 (2015) Maarit Tarkiainen [Finlande] ; Pirjo Tynj L [Finlande] ; Paula V H Salo [Finlande] ; Pekka Lahdenne [Finlande]Occurrence of adverse events in patients with JIA receiving biologic agents: long-term follow-up in a real-life setting.
000E18 (2015) Daisuke Kobayashi [Japon] ; Satoshi Ito ; Akira Hirata ; Asami Abe ; Akira Murasawa ; Ichiei Narita ; Kiyoshi NakazonoMycobacterium abscessus Pulmonary Infection under Treatment with Tocilizumab.
000E54 (????) Thirusha Lane [Royaume-Uni] ; Julian D. Gillmore [Royaume-Uni] ; Ashutosh D. Wechalekar [Royaume-Uni] ; Philip N. Hawkins [Royaume-Uni] ; Helen J. Lachmann [Royaume-Uni]Therapeutic blockade of interleukin-6 by tocilizumab in the management of AA amyloidosis and chronic inflammatory disorders: a case series and review of the literature.
000F00 (2015) Michaela Cellina [Italie] ; Vincenza Fetoni ; Pierluigi Baron ; Marcello Orsi ; Giancarlo OlivaListeria Meningoencephalitis in a Patient With Rheumatoid Arthritis on Anti-Interleukin 6 Receptor Antibody Tocilizumab.
000F71 (2016) Christof Iking-Konert [Allemagne] ; Ulrich Von Hinüber [Allemagne] ; Constanze Richter [Allemagne] ; Holger Schwenke [Allemagne] ; Irmgard Gürtler [Allemagne] ; Peter K Stner [Allemagne] ; Birgit Klapperich [Suisse] ; Marvin A. Peters ; Gerd-Rüdiger Burmester [Allemagne]ROUTINE-a prospective, multicentre, non-interventional, observational study to evaluate the safety and effectiveness of intravenous tocilizumab for the treatment of active rheumatoid arthritis in daily practice in Germany.
001218 (2016) W. Opstelten [Pays-Bas] ; J W J. Bijlsma ; L B S. Gelinck ; C M J. Hielkema ; Th J M. Verheij ; W. Van Eden[Impaired immunity: risk groups and consequences for general practice].
001438 (2017) Robert J. Moots [Royaume-Uni] ; Anthony Sebba [États-Unis] ; William Rigby [États-Unis] ; Andrew Ostor ; Benjamin Porter-Brown [Royaume-Uni] ; Francis Donaldson [Royaume-Uni] ; Sophie Dimonaco [Royaume-Uni] ; Andrea Rubbert-Roth [Allemagne] ; Ronald Van Vollenhoven [Suède] ; Mark C. Genovese [États-Unis]Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials.
001444 (2018) Rossella Talotta [Italie] ; Fabiola Atzeni [Italie] ; Alberto Batticciotto [Italie] ; Maurizio Benucci [Italie] ; Sara Bongiovanni [Italie] ; Piercarlo Sarzi-Puttini [Italie]Biological Agents in Rheumatoid Arthritis: A Cross-Link Between Immune Tolerance and Immune Surveillance.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Ncbi/Checkpoint
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/Mesh.i -k "Opportunistic Infections" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/Mesh.i  \
                -Sk "Opportunistic Infections" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Ncbi
   |étape=   Checkpoint
   |type=    indexItem
   |index=    Mesh.i
   |clé=    Opportunistic Infections
}}

Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021